<DOC>
	<DOCNO>NCT00005097</DOCNO>
	<brief_summary>RATIONALE : Green tea extract contain ingredient may inhibit growth actinic keratosis . PURPOSE : Randomized phase II trial determine effectiveness green tea extract treat patient actinic keratosis .</brief_summary>
	<brief_title>Green Tea Extract Treating Patients With Actinic Keratosis</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy green tea extract epigallocatechin gallate ( Polyphenon E topical ointment ) cause complete clinical histopathologic regression patient actinic keratoses . II . Determine duration treatment Polyphenon E necessary cause regression patient . III . Describe pathophysiologic molecular alteration actinic keratoses sun damage skin present skin sun damage patient . IV . Determine effect treatment biomarkers skin cancer patient . OUTLINE : This randomize , double blind , placebo control study . One patient 's arm randomize receive topical epigallocatechin gallate ( Polyphenon E ) , arm receive placebo . Patients receive topical application daily 12 week , resolution actinic keratoses within treatment field . PROJECTED ACCRUAL : A minimum 60 patient accrue study 10 month .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<criteria>1. participant multiple site actinic keratosis identify clinical examination histologic confirmation one lesion ( Grade 13 define previously `` Clinical Grading '' ) eligible . 2 . No history invasive cancer within 5 year ( though nonmelanoma skin cancer , stage I cervical cancer , chronic lymphocytic leukemia ( CLL ) stage 0 reason exclude patient ) ; severe metabolic disorder lifethreatening acute chronic disease ; additional xray chemotherapy anticipate . 3 . Not require use topical medication area study . 4 . Subjects must meet Southwest Oncology Group performance status criterion 0 1 ( 0= fully active , able carry predisease activity without restriction [ Karnofsky scale 90 100 ] ; 1 = restrict physically strenuous activity , ambulatory able carry work light sedentary nature , i.e . light housework office work [ Karnofsky scale 70 80 ] ) . 5 . Signed informed consent approve local Human Subjects Committee ( Institutional Review Board ) . 1 . Use follow systemic local therapy period specify , prior entry study : Within 2 week : topical medication , e.g . corticosteroid , alphahydroxyacids ( glycolic acid , lactic acid ) retinoids ( RetinA ) target lesion Within 4 week : systemic steroid therapy . Within 2 month : cryotherapy target lesion , laser resurfacing , chemical peel , topical application 5fluorouracil ( 5FU ) masoprocol ( Actinex ) treatment actinic keratoses . Systemic treatment chemotherapeutic agent , psoralens , immunotherapy , retinoids ( Tegison , Accutane ) . 2 . Any medical condition , opinion investigator , could preclude study participation 3 . Active infectious disease tuberculosis ( TB ) HIV may affect patient systemically may also affect immune system . Localized , minor infection sinusitis , uncomplicated urinary tract infection , otitis medium , etc . criterion exclusion study . 4 . Use investigational drug previous 30 day . 5 . Any history keloid formation . 6 . Pregnant nursing patient . 7 . Participants may unreliable study , include engage excessive alcohol intake drug abuse , participant unable return schedule followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>squamous cell carcinoma skin</keyword>
</DOC>